|
Synonyms: compound B201 [WO2023220640]
Compound class:
Synthetic organic
Comment: Reziciclideg is the INN for a cyclin-dependent kinase degrader that was included in WHO INN Proposed List 135 (July 2026). Its structure suggests that it engages the cereblon (CRBN) E3 ubiquitin ligase. The compound is proposed as an antineoplastic agent. Note that the structure here has no specified stereo and is intended to represent the racemic mixture of isomers of the compound. The chemical structure is claimed in BioTheryX patents, for action as a CDK4/6 degrader [1-2]. Reziciclideg is predicted to be the INN for BioTheryX lead CDK4/6 PROTAC BTX-9341.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06515470 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer | Phase 1 Interventional | Biotheryx, Inc. | ||